

List of Figures

Figure 1: Structure of indole with its electronegativity values	1
Figure 2: The molecular structure of cimetidine, a H ₂ -receptor antagonist	9
Figure 3: The molecular structure of omeprazole, a proton pump inhibitor	9
Figure 4: The molecular structure of glibenclamide	14
Figure 5: Halogenated indole Schiff base compounds	18
Figure 6: Copper(II) and nickel(II) complexes of halogenated indole Schiff base compounds	19
Figure 7: Indole hydrazone derivatives where X is H, Cl and Br	29
Figure 8: UV-Vis absorption bands of indolecarboxaldehyde ó indolehydrazide (<i>L1</i>)	34
Figure 9: UV-Vis absorption bands of Ni(indolecarboxaldehyde ó indolehydrazide) ₂ (<i>NiL1</i>)	34
Figure 10: UV-Vis absorption bands of Cu(indolecarboxaldehyde ó indolehydrazide) ₂ (<i>CuL1</i>)	35
Figure 11: The <i>d – d</i> transition band of Cu(indolecarboxaldehyde ó indolehydrazide) ₂ (<i>CuL1</i>)	35
Figure 12: Orbital splitting diagram	37
Figure 13: Crystal structure of indolecarboxaldehyde ó indolehydrazide (<i>L1</i>)	38
Figure 14: Crystal structure of chloroindolecarboxaldehyde ó indolehydrazide (<i>L2</i>)	39
Figure 15: Crystal structure of bromoindolecarboxaldehyde ó indolehydrazide (<i>L3</i>)	40
Figure 16: Crystal structure of Ni(indolecarboxaldehyde ó indolehydrazide) ₂ (<i>NiL1</i>)	41

Figure 17: Crystal structure of Ni(chloroindolecarboxaldehyde ó indolehydrazide) ₂ (<i>NiL2</i>)	42
Figure 18: Crystal structure of Ni(II) bromoindolecarboxaldehyde ó indolehydrazide (<i>NiL3</i>)	43
Figure 19: The neuroprotective effect of halogenated indole Schiff bases and their copper(II) and nickel(II) complexes	45
Figure 20: Lesions area on the stomach of a rat after pretreatment with indolecarboxaldehyde ó indolehydrazide (<i>L1</i>) and its complexes	48
Figure 21: Lesions area on the stomach of a rat after pretreatment with chloroindolecarboxaldehyde ó indolehydrazide (<i>L2</i>) and its complexes	53
Figure 22: Lesions area on the stomach of a rat after pretreatment with bromoindolecarboxaldehyde ó indolehydrazide (<i>L3</i>) and its complexes	56
Figure 23: Percentage inhibition of indole derivatives in ethanol-induced gastric ulcer	59
Figure 24: Percentage of change in blood glucose level after pretreatment with indolecarboxaldehyde ó indolehydrazide (<i>L1</i>) and its complexes	65
Figure 25: Percentage of change in blood glucose level after pretreatment with chloroindolecarboxaldehyde ó indolehydrazide (<i>L2</i>) and its complexes	67
Figure 26: Percentage of change in blood glucose level after pretreatment with bromoindolecarboxaldehyde ó indolehydrazide (<i>L3</i>) and its complexes	69
Figure 27: UV-Vis absorption bands of chloroindolecarboxaldehyde ó indolehydrazide (<i>L2</i>)	91
Figure 28: UV-Vis absorption bands of Cu(chloroindolecarboxaldehyde ó indolehydrazide) ₂ (<i>CuL2</i>)	92
Figure 29: UV-Vis absorption bands of Ni(chloroindolecarboxaldehyde ó indolehydrazide) ₂ (<i>NiL2</i>)	93
Figure 30: UV-Vis absorption bands of bromoindolecarboxaldehyde ó indolehydrazide (<i>L3</i>)	94

Figure 31: UV-Vis absorption bands of Cu(bromoindolecarboxaldehyde ó indolehydrazide) ₂ (CuL3)	95
Figure 32: UV-Vis absorption bands of Ni(bromoindolecarboxaldehyde ó indolehydrazide) ₂ (NiL3)	96
Figure 33: IR spectrum of indolecarboxaldehyde - indolehydrazide (L1)	97
Figure 34: IR spectrum of Cu(indolecarboxaldehyde ó indolehydrazide) ₂ (CuL1)	98
Figure 35: IR spectrum of Ni(indolecarboxaldehyde ó indolehydrazide) ₂ (NiL1)	99
Figure 36: IR spectrum of chloroindolecarboxaldehyde ó indolehydrazide (L2)	100
Figure 37: IR spectrum of Cu(chloroindolecarboxaldehyde ó indolehydrazide) ₂ (CuL2)	101
Figure 38: IR spectrum of Ni(chloroindolecarboxaldehyde ó indolehydrazide) ₂ (NiL2)	102
Figure 39: IR spectrum of bromoindolecarboxaldehyde ó indolehydrazide (L3)	103
Figure 40: IR spectrum of Cu(bromoindolecarboxaldehyde ó indolehydrazide) ₂ (CuL3)	104
Figure 41: IR spectrum of Ni(bromoindolecarboxaldehyde ó indolehydrazide) ₂ (NiL3)	105